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Abstract: Aggressive T cell lymphomas are a subgroup of lymphomas with a particularly 
poor prognosis. This is especially true for patients with recurrent or refractory disease, who 
typically have limited response to salvage therapy and extremely poor overall survival. For 
this reason, there is a strong need to develop potentially active drugs for these malignancies. 
Pralatrexate is a novel antifolate designed to have high affinity for reduced folate carrier type 1. 
Preclinical and clinical studies have demonstrated that pralatrexate has significant activity 
against T cell lymphomas. The dose-limiting toxicity for pralatrexate is mucositis, which can 
be abrogated with folic acid and vitamin B12 supplementation. Pralatrexate is the first single 
agent approved for the treatment of patients with relapsed or refractory peripheral T cell 
lymphoma. This approval was based on an overall objective response rate observed in the 
pivotal study. The overall response rate was 29%, with a median duration of 10.1 months. This 
article reviews the biochemistry, preclinical experience, metabolism, and pharmacokinetics 
of pralatrexate, including the clinical experience with this agent in lymphoma. Future areas 
of development are now focused on identifying synergistic combinations of pralatrexate with 
other agents and the evaluation of predictive markers for clinical benefit.
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Introduction
Over the past 30 years, there has been an increasing understanding of the genetic 
abnormalities and immunological characteristics of non-Hodgkin’s lymphoma (NHL). 
This knowledge has led to further subclassification of NHL, with the recognition 
of new subtypes within both the B cell and T cell categories. In 1994, a group of 
European and US pathologists proposed a new classification of lymphoid neoplasms 
based upon contemporary morphological, immunological, and genetic techniques.1 
This eventually formed the basis for a new World Health Organization classification 
of the hematopoietic and lymphoid neoplasms, utilizing many of the new diagnostic 
techniques in an attempt to recognize all of the existing and new entities.2 This new 
classification system was tested in a cohort of 1403 cases of NHL obtained worldwide 
in the International Non-Hodgkin Lymphoma Classification Project.3 Of these cases, 
only 7% represented a subtype of peripheral T cell lymphoma (PTCL), and 2.4% were 
anaplastic large T/null cell lymphoma. However, even in a study of this size, too few 
cases were present to investigate the various subtypes of PTCL. In Western countries, 
PTCL accounts for 15%–20% of aggressive lymphomas and 5%–10% of all NHLs.4 
In Asia, this number is higher, with 15%–20% of all lymphomas classified as PTCL 
or natural killer T cell lymphoma (NKTCL).4 A large international   retrospective Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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study5 evaluated the various subtypes of lymphoma and 
other disorders found among cases from 22 sites in the US, 
Europe, and Asia. The subtypes documented upon review 
are found in Table 1.
The majority of patients with PTCL present with 
advanced disease, and one third have extranodal involve-
ment at the time of diagnosis. The overall survival for many 
of the subtypes of PTCL and NKTCL is poor. Most aggres-
sive PTCLs and NKTCLs have traditionally been treated 
with an anthracycline-containing regimen, and complete 
response rates of 50%–70% have been reported.6,7 However, 
patients in these studies have a long-term survival of only 
10%–30%. The recent international study confirms the very 
poor prognosis of patients with aggressive forms of PTCL 
and NKTCL. For the most common subtypes, PTCL not 
otherwise specified (NOS) and angioimmunoblastic lym-
phoma, patients treated with an anthracycline-containing 
regimen had the same long-term survival as those treated 
with   nonanthracycline-containing regimens.5   Unfortunately, 
the failure-free survival of patients with high-risk or 
  intermediate-high risk disease ranges from 0% to less than 
10%, with virtually no long-term survivors.8–10 In one such 
study,10 the complete response rate for patients with NKTCL 
was only 43%, while nearly half of all patients were refrac-
tory to their initial upfront chemotherapy.
Collectively, these observations strongly suggest that 
patients with T cell lymphoma are in urgent need of additional 
new treatment options. This is especially true for patients 
with recurrent or refractory disease who typically have lim-
ited response to salvage therapy and extremely poor overall 
survival. Pralatrexate is one agent that, based on strong 
  preclinical and clinical data, is emerging as a promising new 
drug for the treatment of drug-resistant T cell lymphoma.11 
In a Phase II lymphoma study, pralatrexate demonstrated 
activity against PTCL. Subsequently, a multicenter Phase II 
study has led to the approval of pralatrexate in the US for 
relapsed or refractory peripheral T lymphomas.13 The purpose 
of this review was to perform a critical analysis of this drug, 
considering its advantages and disadvantages.
Biochemistry, pharmacology,  
and preclinical experience
Inhibition of the folate enzymes, dihydrofolate reductase and 
thymidylate synthase, is a well validated method of cancer 
treatment. Several antifolate anticancer agents, including 
methotrexate, pemetrexed, and raltitrexed, act via inhibi-
tion of these enzymes.12 Dihydrofolate reductase reduces 
  dihydrofolic acid to tetrahydrofolic acid, a compound that 
is required by dividing cells for the synthesis of thymine. 
Reduced thymine levels following dihydrofolate reductase 
inhibition prevent cell division in rapidly   dividing cancer 
cells.12 The cellular uptake of antifolate agents is mediated 
by reduced folate carrier 1 (RFC-1), and the antifolates 
are retained intracellularly via   polyglutamylation then 
catalyzed by folylpoly-gamma-glutamate synthetase.14 
  Methotrexate, which uses this pathway, has been used to treat 
various types of NHLs, eg, diffuse large B cell lymphoma, 
Burkitt’s lymphoma, and primary central nervous system 
lymphomas.15,16
Tumor cell mutations that inhibit the polyglutamylation 
cellular retention mechanism are a common method of tumor 
resistance to methotrexate.14,17 Thus, compounds with a 
greater affinity for RFC-1 (to improve membrane transport) 
and folylpoly-gamma-glutamate synthetase (to enhance 
polyglutamylation and, therefore, intracellular retention) 
than methotrexate have been designed to enhance antitumor 
activity.18
Pralatrexate is a 10-deazaaminopterin derivative that was 
determined to be a more potent inhibitor of dihydrofolate 
reductase than methotrexate. The improved activity is due to 
the more effective internalization by RFC-1 and subsequent 
accumulation in tumor cells through the formation of polyglu-
tamylated metabolites. These biochemical features suggest 
that pralatrexate should be a more potent antineoplastic agent 
in comparison with methotrexate and could overcome known 
mechanisms of methotrexate resistance, such as downregula-
tion of RFC-1 and/or folylpoly-gamma-glutamate synthetase. 
The cytotoxicity of pralatrexate and methotrexate was com-
pared in parallel in four NHL cell lines by the Memorial 
Sloan Kettering Cancer Center group.19 These studies (sum-
marized in Table 2) included the following cell lines: RL, a 
transformed follicular lymphoma   overexpressing bcl-2; HT, 
Table 1 Distribution of 1314 cases of aggressive T cell lymphoma 
by consensus diagnosis5
Peripheral T cell lymphoma, NOS 25.9%
Angioimmunoblastic T cell lymphoma 18.5%
Natural killer/T cell lymphoma 10.4%
Adult T cell leukemia/lymphoma 9.6%
Anaplastic large cell lymphoma, ALK+ 6.6%
Anaplastic large cell lymphoma, ALK- 5.5%
Enteropathy-type T cell lymphoma 4.7%
Primary cutaneous anaplastic large cell lymphoma 1.7%
Hepatosplenic T cell lymphoma 1.4%
Subcutaneous panniculitis-like T cell lymphoma 0.9%
Unclassifiable peripheral T cell lymphoma 2.5%
Other disorders 12.2%
Abbreviations: NOS, not otherwise specified; ALK, anaplastic lymphoma kinase.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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a diffuse large-cell lymphoma; Hs602, a B cell lymphoma 
derived from a mixed-cell NHL; and   SKI-DLCL-1, a   diffuse 
large-cell lymphoma overexpressing MUC-1. In all cases, 
pralatrexate exhibited 10-fold greater cytotoxicity than 
methotrexate.19
The in vitro experiments demonstrated that pralatrexate 
consistently produced IC50 values 1 log below that   typically 
seen for methotrexate in a library of lymphoma cell lines 
representing a number of different diseases, including 
  diffuse large B cell lymphoma, T cell lymphoma, mantle 
cell lymphoma, and even a very chemotherapy-refractory 
transformed lymphoma carrying the 14:18 translocation.
Another study20 investigated the potential mechanistic 
differences between pralatrexate and other antifolates, 
specifically methotrexate and pemetrexed, in NCI-H460 
nonsmall cell lung cancer cells and MV522 and NCI-H460 
human nonsmall cell lung cancer xenografts. A significantly 
greater proportion of radiolabeled pralatrexate entered the 
cells and was polyglutamylated relative to methotrexate and 
pemetrexed. In vivo, pralatrexate showed superior antitumor 
activity in both nonsmall cell lung cancer models, with more 
effective dose-dependent tumor growth inhibition in the more 
rapidly growing NCI-H460 xenografts.
Pralatrexate was also consistently found to be superior 
to methotrexate in vivo. In a NOD-SCID xenograft model 
of these lymphomas, complete regression of disease was 
observed in mice bearing HT lymphoma following treat-
ment with pralatrexate, while methotrexate-treated mice 
experienced only a 17% reduction in tumor growth. In the 
RL lymphoma xenograft model, mice treated with pralatrex-
ate exhibited significant tumor regression, with two thirds 
of the mice in the pralatrexate-treated group experiencing 
a complete regression of disease, while mice treated with 
methotrexate experienced only a modest growth delay com-
pared with the control group.21
Interestingly, characterization of these cell lines by quan-
titative reverse transcription polymerase chain reaction for 
a number of the determinants of antifolate activity (RFC-1, 
folylpoly-gamma-glutamate synthetase, gamma-glutamyl 
hydrolase) revealed a striking correlation between the level 
of RFC-1 expression and the incidence of complete remis-
sion in the NOD-SCID mouse models, with no instances of 
complete remission observed in any methotrexate-treated 
mouse cohort (Table 3).21
Based upon the single-agent activity of pralatrexate in 
previously reported studies, a series of experiments explor-
ing the integration of pralatrexate with new-generation 
cytidine analogs, most notably gemcitabine, revealed that 
these two agents appear to be synergistic in mouse models 
of lymphomas.
One of the important observations from these studies22 
revolved around the importance of the marked schedule 
dependency. As has been demonstrated for methotrexate and 
cytarabine,22,23 there appears to be a consistent demonstration 
of schedule dependency with pralatrexate and gemcitabine 
as well.
A study of pralatrexate administration in combination with 
gemcitabine in a panel of lymphoma cell lines demonstrated 
that this combination is not only synergistic and more efficient 
than methotrexate/gemcitabine in generating apoptosis, but 
also that the effects were highly sequence-dependent.24 These 
data provide a very strong rationale for combining pralatrexate 
with gemcitabine in future clinical trials.
Metabolism and pharmacokinetics
Following weekly and biweekly administrations of intra-
venous pralatrexate (escalating doses beginning from 
30 mg/m2) to 33 patients with advanced nonsmall cell lung 
Table  3  Correlation  between  complete  remission  rates  to 
pralatrexate and reduced folate carrier type 1 expression in a 
xenograft model of non-Hodgkin’s lymphoma with different cell 
lines21
Cell line Level of expression  
of RFC-1
Complete response   
to pralatrexate
HT 0.96a 90%a
RL 0.41a 55%a
SKI-DLBCL 0.3a 30a
Notes: aAll differences were statistically significant; data from O’Connor.21
Table 2 Cytotoxicity of pralatrexate and methotrexate across a panel of aggressive non-Hodgkin’s lymphoma cell lines21
Cell line Lymphoma subtype Pralatrexate  
IC50 value (nmol/L)
Methotrexate 
IC50 value (nmol/L)
P value
HS445 Hodgkin’s disease 1.6 ± 0.08 32 ± 2.2 0.0455
HT DLBCL 3.0 ± 0.4 35 ± 5 0.0236
RL Transformed large cell lymphoma [t(14:18)] 23 ± 2 210 ± 40 0.0429
SKI-DLBCL DLBCL (ascites) 5.1 ± 0.1 48 ± 2.5 0.0035
Raji Burkitt’s lymphoma 2 ± 0.3 16 ± 0.8 0.0034
Abbreviation: DLBCL, diffuse large B-cell lymphoma.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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cancer in a Phase I clinical trial, the mean area under the 
curve (AUC) values after initial doses of 30, 120, 130, 150, 
and 170 mg/m2 were 5.0, 8.2, 29.8, 20.6, and 30.6 µmol ⋅ h, 
respectively. The mean terminal half-life at a dose of 
150 mg/m2 was eight hours. No changes were observed 
from the first dose to the second dose on the weekly or 
biweekly schedule. Chromatography analysis demonstrated 
the presence of a metabolite, which had a low peak level 
that did not change between days 1 and 15, indicating that 
no induction or inhibition of metabolism had occurred. 
Urinary excretion, measured in two patients, was 6% and 
20% at 24 hours.26
Pharmacokinetic data from 47 patients with hemato-
logical malignancies receiving intravenous pralatrexate 
weekly (30–45 mg/m2) or biweekly (135–240 mg/m2) in a 
Phase I/II clinical trial were modeled in a three-compart-
ment linear model. Patient weight and methylmalonic acid 
(an indicator of vitamin B deficiency) were determined to 
be predictive of interpatient pharmacokinetic variability. 
Increased AUC levels for pralatrexate and methylmalonic 
acid were also predictive of toxicity. The pharmacokinetic 
model assisted in identifying the safest dosing sched-
ule for pralatrexate and supported the need for vitamin 
supplementation.27 An open-label, nonrandomized Phase I 
clinical trial assessed whether supplementation of vitamin 
B12 and folic acid increased the maximum tolerated dose 
of pralatrexate.11 A total of 22 patients with nonsmall cell 
lung cancer received intramuscular vitamin B12 1 mg 
and oral folic acid 1 mg 7 days prior to receiving intra-
venous pralatrexate 150, 190, 230, 270, and 325 mg/m2 
every 2 weeks. The addition of vitamin B12 and folic 
acid was determined to allow higher doses of pralatrexate 
to be administered, and the maximum tolerated dose was 
increased to 270 mg/m2.
Toxicity
The first Phase I study of pralatrexate26 was conducted exclu-
sively in patients with relapsed or refractory nonsmall cell 
lung cancer. Stomatitis became the dose-limiting   toxicity, 
but when pralatrexate was supplemented with vitamin 
B12 and folic acid, stomatitis was reduced in severity and 
frequency.11 Other common adverse events observed were 
mild, including a grade 2 elevation of alanine transferase 
and aspartate transferase (n = 3), a diffuse maculopapular, 
pruritic skin rash (n = 1), and reticulonodular pulmo-
nary infiltrates (n = 1). Significantly, no neutropenia was 
observed.26
When pralatrexate treatment was supplemented with 
vitamin B12 and folic acid in patients with nonsmall cell 
lung cancer, no dose-limiting toxicities were observed at 
pralatrexate doses of 150–230 mg/m2.11 Grade 3 mucositis 
was reported in five of 16 patients receiving the 270 mg/m2 
dose and in two of three patients receiving the 325 mg/m2 
dose. Other common adverse events at all dose levels (n = 22) 
included grade 2 fatigue (n = 10), grade 1 nausea (n = 9), 
grade 1 vomiting (n = 4), and grade 1 rash (n = 4).11
In patients with hematological malignancies, 135 mg/m2 
of pralatrexate administered every 2 weeks was associated 
with an increased risk of high-grade mucositis and   significant 
hematological toxicities, such as thrombocytopenia and 
leukopenia.11 When the dosing schedule was modified to 
weekly doses of 30 mg/m2 of pralatrexate, hematological 
toxicities were reduced by 50%, and no high-grade mucositis 
was observed. Vitamin supplementation also reduced the 
risk of mucositis.11,28
The majority of patients in the Pralatrexate in Patients 
with Relapsed or Refractory Peripheral T-Cell Lymphoma 
(PROPEL) study tolerated pralatrexate. They received 
pralatrexate intravenously at 30 mg/m2/week for 6 weeks in 
7-week cycles. The overall relative dose intensity (delivered 
versus planned doses administered) was 80%. Seventy-six 
patients (68%) remained at the target dose of 30 mg/m2 
for the duration of treatment, and 76 (68%) had one or 
more dose omissions due to adverse events.   Mucositis 
was the most common reason for dose modification. 
Specifically, 23% of patients required dose reduction for 
mucositis. Other reasons for dose reduction were abnor-
mal liver function tests, thrombocytopenia, and fatigue 
(two patients each, 2%), and herpes zoster, leukopenia, 
neutropenia, and pruritic rash (one patient each, ,1%). 
Forty-five percent (n = 50) experienced serious adverse 
events while in the study or #30 days after their last dose 
of   pralatrexate. The most common serious adverse events 
included pyrexia (7%), mucositis (5%), febrile neutropenia 
(5%), sepsis (5%), dehydration (4%), and dyspnea (4%). 
The majority of adverse events were reversible or manage-
able by dose   modification. No cumulative myelosuppres-
sion was observed with continued pralatrexate treatment. 
  Thrombocytopenia, anemia, and neutropenia were rarely 
symptomatic and required supportive care in a minority of 
patients; 15% of patients received a platelet transfusion, 
and 10% received filgrastim.
Twenty-three percent (n = 26) withdrew from treatment 
due to adverse events, and eight (7%) died within 30 days Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of their last dose of pralatrexate. Seven patients died due 
to progression of disease and one patient experienced a 
  cardiopulmonary arrest approximately 3 weeks after the last 
dose of pralatrexate. This death was deemed possibly related 
to pralatrexate.13
Clinical experience with  
pralatrexate in lymphoma
A Phase I/II study of pralatrexate in patients with relapsed 
and refractory NHL and Hodgkin’s lymphoma began in May 
2002 at Memorial Sloan Kettering Cancer Center. Based on 
a Phase I study in patients with nonsmall cell lung cancer, 
the initial Phase II study of pralatrexate in lymphoma used 
a dose of 135 mg/m2 administered as an intravenous bolus 
over 3–5 minutes every other week. A total of 16 patients 
were enrolled on this study, including 15 patients with B cell 
lymphoma and one with a PTCL NOS. This last patient 
enrolled in the study was a middle-aged male with a history of 
very chemotherapy-refractory PTCL NOS, who experienced 
a CT-negative and positron emission tomography-negative 
complete remission following one dose of pralatrexate.21 This 
patient experienced the only durable response to pralatrexate 
known at that time. At this dose, pralatrexate was associated 
with significant grade 3 and 4 stomatitis, which was markedly 
greater than that appreciated in the previous nonsmall cell 
lung cancer studies.26 Based on the observed toxicity, the 
study was amended to a Phase I/II study in which pralatrexate 
was scheduled weekly. Dose-limiting toxicity was seen at 
45 mg/m2, and thus, 30 mg/m2 weekly × 6 weeks for every 
7-week cycle was chosen as the maximum tolerated dose.28
On this revised schedule, 40 patients with Hodgkin’s 
lymphoma, diffuse large B cell lymphoma, and T cell 
lymphoma were recruited (total n = 56 overall). In the 
most recent report of results for this trial, the overall 
response in 46 evaluable patients was 35%.11 In patients 
with B cell and T cell lymphoma (n = 20 and n = 26 evalu-
able patients, respectively), the overall response rates were 
10% and 54%, respectively. Complete remissions were 
observed in nine patients with T cell lymphoma, and partial 
remissions occurred in five patients and two patients with 
T cell and B cell lymphomas, respectively; the duration of 
  remission was 3–24 months. Durable complete remissions 
were observed in the following subtypes of cancer: acute 
  lymphoblastic (12 months), human T cell leukemia virus 
type 1 adult T cell leukemia/lymphoma ($21 months; n = 3), 
blastic NKTCL (8 months), anaplastic lymphoma kinase 
(+) anaplastic large cell   cancer ($10 months), PTCL NOS 
(3 months),   subcutaneous   panniculitis-like T cell lymphoma 
(9 months) and γ, δ-subcutaneous panniculitis-like T cell 
lymphoma (9 months). Most of the responding patients 
had been   refractory to previous chemotherapy, including 
methotrexate.
A case of a woman with a rare, highly aggressive CD4+ 
CD56+ hematodermic/plasmacytoid dendritic cell tumor has 
been reported. The tumor had relapsed quickly after previous 
treatment with cyclophosphamide, doxorubicin, vincristine, 
and prednisone chemotherapy and was treated with weekly 
intravenous doses of pralatrexate 30 mg/m2 supplemented 
with folic acid and vitamin B12 every 4 weeks. After six 
infusions, a durable response was observed, and skin tumors 
regressed, indicating the potential use of pralatrexate for this 
malignancy.30
On September 24, 2009, the Office of Oncology Drug 
Products granted accelerated approval of pralatrexate injec-
tion for the treatment of patients with relapsed and refractory 
PTCL. This approval was based on the overall objective 
response rate observed in PROPEL. The PROPEL study was 
an open-label, nonrandomized, multicenter, international 
clinical trial that enrolled 115 patients with PTCL who had 
relapsed or had progressive disease following prior therapy. 
Sixty-three percent did not have an objective response to the 
most recent prior therapy. One hundred and nine evaluable 
patients received pralatrexate at a starting dose of 30 mg/m2 
administered as an intravenous push over 3–5 minutes once 
weekly for 6 weeks followed by a 1-week break (one cycle). 
In addition, each patient received vitamin B12 1.0 mg 
intramuscularly every 8–10 weeks and daily administration 
of folic acid 1.0–1.25 mg orally. Imaging scans to assess 
disease status were performed at week 7 (end of cycle 1) 
and subsequently at 14-week intervals. The primary end-
point of the study was overall response rate. In the evalu-
able patient population (n = 109), the overall response rate 
(complete remission plus complete remission unconfirmed 
plus partial response) was 29% (95% confidence interval 
[CI], 21–39), as assessed by independent central review. 
Twelve patients (11%) achieved a complete   remission/
unconfirmed complete remission, 20 (18%) achieved a 
partial response, and 21 (19%) experienced stable disease. 
Of the 26 patients who did not have responses to any prior 
conventional therapy, five (19%) responded to pralatrexate. 
The majority of responding patients responded quickly; 63% 
of all responses occurred within the first cycle of pralatrexate, 
but responses were observed as late as cycle 7. The median 
duration of response was 10.1 months, with a range of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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1–673 days. Among the 32 responders, 16 (50%) progressed 
or died, five (16%) were still responding, and 11 (34%) were 
  censored as   follows: four transplants (two autologous and 
two   allogeneic), subsequent therapy (n = 3), or study termi-
nation (n = 4).   Interestingly, only two patients who attained 
a complete remission developed progressive disease. Nine 
patients had responses exceeding 300 days in duration, four 
of whom remained on treatment at the time of data cutoff. 
At the time of last follow-up, all four of the patients still in 
response (three complete remissions, one partial response) 
at the time of stem cell transplant (SCT) remained alive and 
had received no further therapy. The median progression-
free survival was 3.5 months (95% CI 1.7–4.8), with a range 
of 1 day to 23.9 months. The median overall survival was 
14.5 months (95% CI 10.6–22.5), with a range of 1.0 to 
24.1 months. Forty-three percent were censored for overall 
survival because they were alive at the data cutoff date. The 
median follow-up time for all patients still alive at the time 
of the analysis was 18 months.13
Other analysis evaluated SCT use before or after 
  pralatrexate in the PROPEL study. Of the 109 patients 
who were evaluable for response, six (6%) went on to SCT 
(two autologous SCT, four allogeneic SCT) as their initial 
subsequent therapy after responding to pralatrexate, accord-
ing to investigator assessment of response. Four of these 
patients were still in response by central review at the time 
they started SCT. At the time of data cutoff, no additional 
therapy had been administered to any of these four patients 
following SCT. The other two patients had partial responses 
by   investigator review and progressive disease by central 
review at the time SCT was started, and neither of these 
patients had additional therapy documented after SCT. All 
six patients were alive at the time of last contact.32
A US Food and Drug Administration review of the 
  PROPEL data31 indicated that only 13 (12%, 95% CI 7–20) of 
the responses were maintained for $14 weeks (time   interval 
between scans). Sixteen of 29 responders had   durations 
of response less than 14 weeks (10 developed progres-
sive   disease on subsequent scans, three had no subsequent 
  imaging scans because of off-study treatment, and three 
responders were censored).
Combinations with other drugs
Pralatrexate and gemcitabine each have activity as 
  monotherapy in patients with relapsed or refractory 
  lymphoma. Preclinical data reported synergy for the 
  combination of these drugs in NHL cell lines and xenografts 
that was schedule-dependent.24 A multicenter Phase I/IIa 
study (PDX-009, NCT00481871) was initiated to evalu-
ate this treatment combination. The primary objective 
of the Phase I portion was to determinate the maximum 
  tolerated dose and optimal Phase II dose and schedule for 
the   combination of pralatrexate and gemcitabine in patients 
with relapsed or refractory lymphoma.
As of May 2009, 34 patients were treated in the Phase I 
portion, including 24 men (71%), and the median age was 
63 (range 19–81) years. Histology included 13 patients with 
B cell lymphoma, 11 with NKTCL, seven with Hodgkin’s 
lymphoma, and three with “other” lymphoma. Patients had 
received a median of 3.5 (range 1–11) prior regimens. All 
patients with once-weekly sequential day dosing   (pralatrexate 
10–15 mg/m2 and gemcitabine 300–400 mg/m2) in group 
A had dose-limiting toxicities of thrombocytopenia and/
or neutropenia. Therefore, accrual to this schedule was 
halted, and subsequent cohorts received pralatrexate with 
gemcitabine on a twice-weekly schedule (groups B and C). 
The   maximum tolerated dose with the twice-weekly   dosing 
  schedule was pralatrexate/gemcitabine 10/400 mg/m2 when 
given on sequential days (group B) and 15/600 mg/m2 
when given on the same day (group C). Of 33 patients who 
were evaluable for response, seven (21%) showed a partial 
response, including patients with Hodgkin’s lymphoma 
(n = 4),   diffuse large B cell lymphoma (n = 1), angioimmuno-
blastic T cell lymphoma (n = 1), and composite diffuse large 
B cell   lymphoma and T cell lymphoma (n = 1). Responses 
were seen in patients treated on the same day as well as on 
the sequential day schedule. The dose-limiting toxicities 
for group B were cellulitis, pulmonary embolus, thrombo-
cytopenia, and febrile neutropenia, and the dose-limiting 
toxicities for group C were fatigue, hypoxia, mucositis, and 
  thrombocytopenia. Across all groups, the most frequently 
reported grade 3–4 pralatrexate-related adverse events were 
neutropenia (41%), thrombocytopenia (35%), anemia (29%), 
and leukopenia (12%). Treatment with pralatrexate and gem-
citabine is feasible, with acceptable toxicity, when adminis-
tered on a twice-weekly schedule. However, the maximum 
tolerated dose of each group is 50% greater when given on the 
same day compared with treating on sequential days. Phase 2 
expansions of the maximum tolerated dose will explore both 
sequential-day dosing (10/400 mg/m2) and same-day dosing 
(15/600 mg/m2) in a twice-weekly schedule.24
Conclusion
The prognosis for patients with newly diagnosed aggressive 
PTCL is poor for most subtypes. PTCLs have the lowest 
5-year survival rates among the NHL subtypes, including Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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mantle cell lymphoma. Clearly, better therapeutic regimens 
are needed to improve the long-term outcome of these 
patients. Pralatrexate, a novel aminopterin with high affin-
ity for the reduced folate carrier, appears to demonstrate 
significant activity in a select subpopulation of patients 
with T cell lymphoma, including patients with a variety of 
precursors and PTCL. At this time, the clinical benefit of 
pralatrexate, such as improvement in overall or progression-
free survival, has not been shown. However, the magnitude 
of the pralatrexate effect (ie, 12% responses lasting at least 
14 weeks) most likely predicts clinical benefit in this previ-
ously heavily treated patient population (median of three 
prior therapies) with a rare disease, in which no therapies 
are currently approved.
Future areas of development have now focused on identify-
ing synergistic combinations of other agents with pralatrexate, 
including gemcitabine, bortezomib, and histone deacetylase 
inhibitors. The problem has now evolved into an abundance of 
drugs with too few patients available for testing.   Collaborative 
groups will aid in future efforts to find the best treatment 
  strategies to improve the outcome for patients with PTCL.
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